In this new research study, PredicineWES™ boosted whole exome sequencing was used to analyze circulating tumor DNA (ctDNA) to identify genomic features for predicting and monitoring treatment resistance.
January 2023
Read More
In this new research study, PredicineATLAS™ liquid biopsy next-generation sequencing assay was used to compare gemcitabine and nab-paclitaxel with and without immune checkpoint inhibitors durvalumab and tremelimumab in 180 patients with mPDAC. The primary endpoint was overall survival. Secondary endpoints included progression-free survival and objective response rate.
August 2022
Read More
In this new research study, PredicineCARE™ liquid biopsy next-generation sequencing assay assessed the correlations between circulating tumour DNA (ctDNA)-derived genomic markers and treatment response and survival outcome in Chinese patients with advanced breast cancer (ABC).
May 2022
Read More
In this new research study, PredicineATLAS™ (Assay B) liquid biopsy next-generation sequencing assay demonstrated superior performance compared to four other leading commercial liquid biopsy assays.
May 2022
Read More
In this study, the PredicineATLAS™ panel was used to detect germline variants in Chinese patients with advanced breast cancer.
April 2022
Read More
In this study, PredicineATLAS™ liquid biopsy study is used to evaluate gemcitabine and cisplatin plus durvalub with or without tremelimumab as first-line treatment in patients with advanced biliary tract cancer.
March 2022
Read More
In this study, PredicineCARE™ is used to evaluate circulating tumor DNA (ctDNA) in blood or urine, which can be used as biomarkers of PCa and the combination of these markers may increase the sensitivity and specificity of the detection of PCa.
March 2022
Read More
In this study, PredicineCARE™ is used to perform a retrospective analysis of serially profiled cell-free DNA (cfDNA) alterations in blood samples collected from mCRPC patients before and after starting chemotherapy who were followed for response and clinical outcomes.
March 2022
Read More
In this study, Predicine’s GeneRADAR technology and DeepSea machine learning is used to assess the association between the poor prognostic 3-lipid signature (3LS), somatic genetic aberrations and clinical outcomes in mCRPC.
March 2022
Read More
Predicine’s cfDNA and cfRNA assays were utilized to assess the role of somatic alterations on treatment resistance in patients with metastatic castration-resistant prostate cancer.
October 2021
Read More
Utilizing the PredicineCARETM assay, this study demonstrates that urinary tumor DNA (utDNA) outperformed circulating tumor DNA (ctDNA) from blood samples in identifying somatic alterations in patients with newly diagnosed urothelial bladder cancer.
September 2021
Read More
The PredicineCARETM liquid biopsy assay was utilized to evaluate the correlation between genomic alterations and progression-free survival in patients with hormone-receptor positive metastatic breast cancer in the US and China
September 2021
Read More
In a study of patients with mCRPC, the PredicineCARETM and PredicineRNA liquid biopsy assays were utilized to identify alterations that may be associated with a poorer prognosis. The study also demonstrated that serial testing of cfDNA offers the unique opportunity to predict benefit to therapy prior to the onset of biochemical or radiographic changes.
September 2021
Read MoreThe PredicineCARETM liquid biopsy assay was utilized to identify PTEN, RB1 and TP53 copy number losses in plasma samples from patients with metastatic prostate cancer. These findings have profound clinical implications for a patient’s prognosis, treatment selection, and understanding subsequent resistance.
August 2021
Read moreUsing PredicineATLAS™ to analyze somatic mutations and copy number changes in PI3K/AKT pathway, NOTCH signaling pathway, hedgehog signaling pathway and pathways involved in DNA damage repair might be potential mechanisms underlying TKI resistance.
May 2021
Read moreUsing PredicineCARE™ to analyze TP53 mutations in cell-free DNA from patients with metastatic breast cancer to investigate disease characteristics and the prognostic role of different locations of the TP53 mutation site.
April 2021
Read morePTEN-PI3K-AKT pathway CNVs were detected using Predicine’s cfDNA liquid biopsy assay, with the prevalence of PTEN loss comparable with tissue-based studies. Plasma cfDNA profiling may facilitate and optimize patient selection for targeted treatment with Akt inhibitors in mCRPC.
April 2021
Read moreUsing PredicineCARE™ to analyze mutational landscape of 158 tumor related genes in HER2-positive breast cancer patients.
November 2020
Read moreUsing PredicineCARE™ to detect CXCR4 mutations in bone marrow samples of Waldenström macroglobulinemia patients for patient stratification.
November 2020
Read moreThe first prospective observational clinical study that simultaneously investigates cfDNA and cfRNA focusing on AR biomarkers in two independent mCRPC cohorts.
May 2020
Read moreAn editorial to introduce an upcoming study that leverages Predicine’s next-gen liquid biopsy technology to investigate plasma cfDNA- and cfRNA-based AR molecular profiling in metastatic castration-resistant prostate cancer.
May 2020
Read moreUsing Predicine’s cfDNA assay to analyze the molecular evolution over the mutational landscape from mSHPC to mCRPC. Gene deletion and amplification of BRCA, PTEN, RB, AR are reported.
April 2020
Read moreUsing Predicine’s cfDNA assay to analyze the relationship between BRCA gene status and the efficacy of platinum- and non-platinum-based regimens as first-line treatment for advanced TNBC.
February 2020
Read moreValidation of Predicine’s ctDNA assay reporting high concordance of variant detection in orthogonal samples between Predicine and Guardant Health’s ctDNA platforms.
January 2020
Read moreThe potential of combining CTCs and ctDNA for comprehensive liquid biopsy analysis to accurately represent genomic heterogeneity with implications for clinical management of patients with MBC.
December 2019
Read moreJune 2023
Read More
June 2023
Read More
April 2023
Read More
April 2023
Read More
April 2023
Read More
April 2023
Read More
April 2023
Read More
April 2023
Read More
April 2023
Read More
February 2023
Read More
February 2023
Read More
February 2023
Read More
Nathan Standifer, PhD; Yonchu Jenkins; Sam H. Whiting, MD, PhD; Thomas W. Dubensky, Jr., PhD;
November 2022
Zheng Feng, PhD, MD; Neil R. Smith, PhD; Giancarlo Bonora, PhD; Juergen Scheuenpflug; Pan Du
November 2022
Jingyu Zhang, Ruiyun Zhang, Feng Xie, Yue Zhang, Pan Du, Shidong Jia, Haige Chen, Guanglei Zhuang
September 2022
Read More
Andrew A. Davis, Jingqin Luo, Tiantian Zheng, Chao Dai, Rama Suresh, Foluso Ademuyiwa, Caron Rigden, Katherine Clifton, Katherine Weilbaecher, Ashley Frith, Pavan K. Tandra, Tracy Summa, Shana Thomas, Lindsay Peterson, Xiaohong Wang, Pan Du, Shidong Jia, Bonnie L. King, Jairam Krishnamurthy, Cynthia X. Ma
September 2022
Read More
Roger Li, Giancarlo Bonora, Chao Dai, Binggang Xiang, Hang Dong, Wei Mo, Xiaohong Wang, Kemin Zhou, Shidong Jia, Shujun Luo, Pan Du
September 2022
Read More
Heather L Huelster, Elizabeth A. Green, Alex C. Soupir, Kyle M. Rose, Esther N. Katende, Shreyas U Naidu, Scott Michael Gilbert, Brandon J. Manley, Michael Adam Poch, Wade J. Sexton, Alice Yu, Philippe E. Spiess, Pan Du, Shidong Jia, Il-Jin Kim, Lu Tan, Liang Wang, Roger Li
May 2022
Read More
Heather Huelster, Elizabeth A. Green, Alex C. Soupir, Esther N. Katende, Kyle M. Rose, Shreyas U. Naidu, Scott Michael Gilbert, Brandon J. Manley, Michael Adam Poch, Wade J. Sexton, Philippe E. Spiess, Alice Yu, Youngchul Kim, Pan Du, Shidong Jia, Il-Jin Kim, Lu Tan, Liang Wang, Roger Li
February 2022
Read more
Heidi Fettke, Christine Hauser, Edmond Kwan, Chao Dai, Tiantian Zheng, Amy Wang, Winston Tan, Pan Du, Nicole Ng, Patricia Bukczynska, Siavash Foroughi, Lisa-Jane K. Graham, Lisa Horvath, Kate Lynette Mahon, Shidong Jia, Manish Kohli, Arun Azad
February 2022
Read more
Andrea Knox, Heidi Fettke, Christine Hauser, Patricia Bukczynska, Nicole Ng, Siavash Foroughi, Lisa-Jane K. Graham, Kate Lynette Mahon, Winston Tan, Tiantian Zheng, Chao Dai, Pan Du, Shidong Jia, Lisa Horvath, Manish Kohli, Arun Azad, Edmond Kwan, Amy Wang
February 2022
Read more
Ruiyun Zhang, Jingyu Zang, Feng Xie, Yue Zhang, Akezhouli Shahatiaili, Yiqiu Wang, Pan Du, Shidong Jia, Guanglei Zhuang, Yiran Huang, Haige Chen
February 2022
Read more
Feng Xie, Jingyu Zang, Yue Zhang, Ruiyun Zhang, Yong Huang, Guanglei Zhuang, Haige Chen, Pan Du, Shidong Jia
February 2022
Read more
Andrew Davis, Jingqin Luo, Tiantian Zheng, Lu Tan, Amy Wang, Rama Suresh, Foluso Ademuyiwa, Caron Rigden, Timothy Rearden, Katherine Clifton, Katherine Weilbaecher, Ashley Frith, Pavan K Tandra, Tracy Summa, Brittney Haas, Shana Thomas, Leonel Hernandez-Aya, Lindsay Peterson, Shujun Luo, Bonnie L King, Shidong Jia, Jiajun Yu, Pan Du, Jairam Krishnamurthy, Cynthia X Ma
December 2021
Read more
Lorenzo Gerratana, Qiang Zhang, Andrew A Davis, Ami N Shah, Jianjun Yu, Shidong Jia, Youbin Zhang, Firas Wehbe, Amir Behdad, Leonidas C Platanias, William J Gradisha, and Massimo Cristofanilli
December 2019
Read more
Lorenzo Gerratana, Qiang Zhang, Ami N Shah, Alessandra Franzoni, Jianjun Yu, Shidong Jia, Andrew A Davis, Youbin Zhang, Firas Wehbe, Amir Behdad, Leonidas C Platanias, William J Gradishar and Massimo Cristofanilli
December 2019
Read more
Manish Kohli, Winston Tan, Tiantian Zheng, Amy Wang, Calvin Wong, Meng-Yao Tan, Shidong Jia, Jianjun Yu; H. Lee
June 2019
Read more
Heidi Fettke, Edmond M. Kwan, Jianjun Yu, Amy Wang, Carlos Montesinos, Calvin Wong, Xue Gong, Tiantian Zheng, Peter Pan Du, Shidong Jia, Andrew Mant, Phillip Parente, Carmel Pezaro, Arun A. Azad
April 2019
Read more
Zhixin Zhao, Amy Chang, Tak Cheung, Feng Xie, Carlos Montesinos, Amy Xiaohong Wang, Kemin Zhou, Shidong Jia, JIanjun Yu, Pan Du
April 2019
Read more
Manish Kohli, Siddhartha Yadav, Winston Tan, Irbaz Bin Riaz, Tiantian Zheng, Amy Wang, Carlos Montesinos, Calvin Wong, Peter Du, Shidong Jia, Jianjun Yu
February 2019
Read more
Ready to streamline your precision oncology clinical research programs? Submit your information to speak to a team member.